Oncolytics Biotech Inc logo

ONCY - Oncolytics Biotech Inc Share Price

$2.44 -0.0  -1.6%

Last Trade - 9:00pm

Sector
Healthcare
Size
Small Cap
Market Cap £77.9m
Enterprise Value £60.1m
Revenue £n/a
Position in Universe 4154th / 6363
Bullish
Bearish
Unlock ONCY Revenue
Momentum
Relative Strength (%)
1m
3m
6m
1yr
Volume Change (%)
10d / 3m
Price vs... (%)
52w High
50d MA
200d MA
Margin of Safety
Qualifying GuruScreens
Financial Summary
FINANCIAL BRIEF: : For the three months ended 31 March 2020, Oncolytics Biotech Inc. revenues was not reported. Net income totaled C$400K vs. loss of C$4.9M. Net income reflects Change in fair value of warrant derivati increase from C$0K to C$4.2M (income), Foreign exchange gain (loss) increase from C$145K (expense) to C$1.7M (income), Research and development - Balancing val decrease of 17% to C$2.4M (expense).
Health Trend(F-Score)
0 1 2 3 4 5 6 7 8 9
Bankruptcy Score(Z-Score)
Distress
Cautious
Safe
Earnings Manipulation Risk(M-Score)
Other Ratios
Recent History
Latest interim period vs. prior period Industry Market
3yr Compound Annual Growth Rate Industry Market
Graphical History

Revenue

ONCY Revenue Unlock ONCY Revenue

Net Income

ONCY Net Income Unlock ONCY Revenue

Normalised EPS

ONCY Normalised EPS Unlock ONCY Revenue

PE Ratio Range

ONCY PE Ratio Range Unlock ONCY Revenue

Dividend Yield Range

ONCY Dividend Yield Range Unlock ONCY Revenue
Analyst Forecasts
Price Target:
( below Price)
31st Dec 2020
31st Dec 2021
Est. Long Term Growth Rate: Net Profit
()
EPS
()
DPS
()
Net Profit
()
EPS
()
DPS
()
Consensus Estimate
1m Change
3m Change
Analyst Consensus
Strong Sell Sell Hold Buy Strong Buy
EPS 2019 /  2020
ONCY EPS Forecasts Unlock ONCY Revenue
Profile Summary

Oncolytics Biotech Inc. is a development-stage company. The Company is focused on the development of REOLYSIN, its cancer therapeutic. The Company's clinical program is made up of a registration program that includes muscle-invasive bladder cancer and glioma cancer, over six randomized Phase II clinical trials and approximately six other investigative clinical trials. The Company focuses on the registration of REOLYSIN in approximately two indications, including the neoadjuvant treatment of muscle-invasive bladder cancer and the treatment of glioblastoma. The Company has conducted a single arm United States Phase II non-small cell lung cancer (NSCLC) trial and a single arm United States Phase II pancreatic cancer trial for REOLYSIN. The Company is also engaged in conducting a Phase Ib trial for REOLYSIN and chemotherapy in combination with pembrolizumab in its Checkpoint Inhibitor Program.

Directors
Last Annual December 31st, 2019
Last Interim March 31st, 2020
Incorporated April 2, 1998
Public Since June 1, 2000
No. of Shareholders: n/a
No. of Employees: 30
Sector Healthcare
Industry Biotechnology & Medical Research
Index Nasdaq Composite ,
Exchange NASDAQ Capital Market (Dual Listing)
Shares in Issue 39,289,208
Free Float (0.0%)
Eligible for
ISAs
SIPPs
ONCY Share Price Performance
Share Price
Bid - Ask
Low - High
Spread
Day's Change
Avg Volume
Open - Close
Range (12m)
Beta
Latest News for ONCY
Upcoming Events for ONCY
Frequently Asked Questions for Oncolytics Biotech Inc
What is the Oncolytics Biotech Inc share price?

As of 9:00pm, shares in Oncolytics Biotech Inc are trading at $2.44, giving the company a market capitalisation of £77.9m. This share price information is delayed by 15 minutes.

How has the Oncolytics Biotech Inc share price performed this year?

Shares in Oncolytics Biotech Inc are currently trading at $2.44 and the price has moved by 34.78% over the past 365 days. In terms of relative price strength - which takes into account the overall market trend - the Oncolytics Biotech Inc price has moved by 23.81% over the past year.

What are the analyst and broker recommendations for Oncolytics Biotech Inc?

Of the analysts with advisory recommendations for Oncolytics Biotech Inc, there are there are currently 1 "buy" , 0 "hold" and 0 "sell" recommendations. The overall consensus recommendation for Oncolytics Biotech Inc is Buy. You can view the full broker recommendation list by unlocking its StockReport.

When will Oncolytics Biotech Inc next release its financial results?

Oncolytics Biotech Inc is scheduled to issue upcoming financial results on the following dates:

Interim results are scheduled for: 2021-03-31
What is the Oncolytics Biotech Inc dividend yield?

Oncolytics Biotech Inc does not currently pay a dividend.

Does Oncolytics Biotech Inc pay a dividend?

Oncolytics Biotech Inc does not currently pay a dividend.

When does Oncolytics Biotech Inc next pay dividends?

Oncolytics Biotech Inc does not currently pay a dividend.

How do I buy Oncolytics Biotech Inc shares?

To buy shares in Oncolytics Biotech Inc you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.

What is the market cap of Oncolytics Biotech Inc?

Shares in Oncolytics Biotech Inc are currently trading at $2.44, giving the company a market capitalisation of £77.9m.

Where are Oncolytics Biotech Inc shares listed? Where are Oncolytics Biotech Inc shares listed?

Here are the trading details for Oncolytics Biotech Inc:

Country of listing: United States
Exchange: NAQ
Ticker Symbol: ONCY
What kind of share is Oncolytics Biotech Inc?

Based on an overall assessment of its quality, value and momentum, Oncolytics Biotech Inc is currently classified as a Momentum Trap. The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.

Is there a Oncolytics Biotech Inc share price forecast 2020?

Shares in Oncolytics Biotech Inc are currently priced at $2.44. At that level they are trading at 0.134% discount to the analyst consensus target price of 0.00.

Analysts covering Oncolytics Biotech Inc currently have a consensus Earnings Per Share (EPS) forecast of -0.8 for the next financial year.

How can I tell whether the Oncolytics Biotech Inc share price will go up?

An important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like Oncolytics Biotech Inc. Over the past six months, the relative strength of its shares against the market has been 0.127k%. At the current price of $2.44, shares in Oncolytics Biotech Inc are trading at 54.95% against their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.

What is the Oncolytics Biotech Inc PE Ratio?

We were not able to find PE ratio data for Oncolytics Biotech Inc.

Who are the key directors of Oncolytics Biotech Inc?

Oncolytics Biotech Inc's management team is headed by:

Matthew Coffey - PRE
Wayne Pisano - CHM
Mary Dillahunty - VPR
Andres Gutierrez - OTH
Alan Tuchman - OTH
George Gill - SVP
Deborah Brown - DRC
Kirk Look - CFO
Angela Holtham - DRC
J. Mark Lievonen - DRC
Edwin Levy - DRC
Leonard Kruimer - DRC
Who are the major shareholders of Oncolytics Biotech Inc?

Here are the top five shareholders of Oncolytics Biotech Inc based on the size of their shareholding:

Seizinger (Bernd R.) Individual Investor
Percentage owned: 0.49% (193k shares)
Two Sigma Investments, LP Hedge Fund
Percentage owned: 0.38% (151k shares)
Pisano (Wayne) Individual Investor
Percentage owned: 0.3% (116k shares)
Creative Planning, Inc. Investment Advisor/Hedge Fund
Percentage owned: 0.24% (93.0k shares)
Holtham, Angela Frances Individual Investor
Percentage owned: 0.18% (69.6k shares)
Similar to ONCY
© Stockopedia 2020, Refinitiv, Share Data Services.
This site cannot substitute for professional investment advice or independent factual verification. To use it, you must accept our Terms of Use, Privacy and Disclaimer policies.